Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
language:"Undetermined"
format_facet:"Aufsätze"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=language%3A%22Undetermined%22&filter%5B%5D=format_facet%3A%22Aufs%C3%A4tze%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields&page=6
/vufind/Search/Results?filter%5B%5D=language%3A%22Undetermined%22&filter%5B%5D=format_facet%3A%22Aufs%C3%A4tze%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields&page=6
Search /vufind/Search2/Results?filter%5B%5D=language%3A%22Undetermined%22&filter%5B%5D=format_facet%3A%22Aufs%C3%A4tze%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields&page=6
PubPharm (286)
51
Hydrodilatation in adhesive capsulitis, Intra-articular corticosteroid in adhesive capsulitis : A Comparative study between intra-articular corticosteroid injection and ultrasound-guided hydrodilatation in patients with shoulder adhesive capsulitis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
52
A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma : AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR LINES OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
53
A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma : AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR LINES OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
54
SeluDex : International phase I/II expansion trial of the MEK inhibitor selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult Acute Lymphoblastic Leukaemia - SeluDex
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
55
SeluDex : International phase I/II expansion trial of the MEK inhibitor selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult Acute Lymphoblastic Leukaemia - SeluDex
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
56
Randomized Phase 3 study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) versus Pomalidomide-Dexamethasone (PD) in relapse or refractory myeloma. An AMN study : Randomized Phase 3 study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) versus Pomalidomide-Dexamethasone (PD) in relapse or refractory myeloma. An AMN study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
57
Randomized Phase 3 study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) versus Pomalidomide-Dexamethasone (PD) in relapse or refractory myeloma. An AMN study : Randomized Phase 3 study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) versus Pomalidomide-Dexamethasone (PD) in relapse or refractory myeloma. An AMN study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
58
SeluDex : International phase I/II expansion trial of the MEK inhibitor selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult Acute Lymphoblastic Leukaemia - SeluDex
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
59
SeluDex : International phase I/II expansion trial of the MEK inhibitor selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult Acute Lymphoblastic Leukaemia - SeluDex
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
60
Carfilzomib + Lenalidomide +Dexamethasone for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas : Carfilzomib (K) plus Lenalidomide (R) and Dexamethasone (D) for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas: a phase II study - FIL_KLIMT
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
[1]
« Vorheriger
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[29]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Sprache: Unbestimmt
Filter aufheben
Medienart: Aufsätze
Medienart
Aufsätze
284
E-Artikel
284
E-Ressourcen
2
Gedruckte Aufsätze
Zeitschriftentitel
170
WHO International Clinical Trials Registry Plat...
114
Europäisches Patentamt
1
Journal of biomaterials and tissue engineering
1
Science of advanced materials
Thema
122
610
118
Study Type: Interventional
114
615
114
che
101
A61K
72
A61P
38
Recruitment Status: Authorised-recruitment may ...
36
Recruitment Status: Completed
30
Phase: Phase 3
20
Recruitment Status: Not yet recruiting
20
Recruitment Status: Recruiting
16
Medical Condition: MULTIPLE MYELOMA MedDRA vers...
13
Medium
9
A61K: Preparations for medical, dental, or toil...
8
A61M
8
Phase: Phase 1
6
C12N
6
Medical Condition: Atopic Dermatitis
6
Phase: Phase 2
6
Phase: Phase 4
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
148
2020-
138
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
Unbestimmt
Haven't found what you're looking for?
Wird geladen...